U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Pluri's cell therapy is designed to be the first in class, effective treatment for ionizing radiation poisoning in the event of a large-scale nuclear incident.The work specified by the contract is...

Related Keywords

Maryland ,United States ,Berlin ,Germany ,Israel ,National Institutes Of Health ,Vijayk Singh ,Christiem Orschell ,Sanchita Ghosh ,Nathan Miller ,Yaky Yanay ,Shachar Yental ,Meira Feinman ,Pluri Inc ,Nasdaq ,Twitter ,Linkedin ,Us Department Of Defense ,Indiana University Prof ,Us Strategic National ,Armed Forces Radiobiology Research Institute ,Nuclear Disaster ,Drug Administration ,Uniformed Services University Of Health Sciences ,Us National Institute Of Allergy ,Globenewswire Inc ,Exchange Commission ,National Stockpile ,Infectious Diseases ,Forces Radiobiology Research Institute ,Services University ,Health Sciences ,Hematopoietic Acute Radiation Syndrome ,Investigational New Drug ,Orphan Drug ,Private Securities Litigation Reform Act ,Investor Relations ,